Published in Diabetes on May 01, 2005
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol (2010) 1.12
The complement system in ischemia-reperfusion injuries. Immunobiology (2012) 1.10
Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia (2008) 1.08
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol (2011) 0.96
A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am J Reprod Immunol (2008) 0.93
Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. J Immunol Methods (2007) 0.89
Gene expression differences in skin fibroblasts in identical twins discordant for type 1 diabetes. Diabetes (2012) 0.89
Mannan-binding lectin in diabetic kidney disease: the impact of mouse genetics in a type 1 diabetes model. Exp Diabetes Res (2012) 0.88
Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes (2009) 0.87
Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev (2015) 0.82
Murine hyperglycemic vasculopathy and cardiomyopathy: whole-genome gene expression analysis predicts cellular targets and regulatory networks influenced by mannose binding lectin. Front Immunol (2012) 0.81
SNP and gene networks construction and analysis from classification of copy number variations data. BMC Bioinformatics (2011) 0.81
Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model. J Diabetes Res (2016) 0.78
Complement activation in progressive renal disease. World J Nephrol (2015) 0.77
Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One (2015) 0.77
Ficolin B in Diabetic Kidney Disease in a Mouse Model of Type 1 Diabetes. Mediators Inflamm (2015) 0.77
Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels. Kidney Int Suppl (2011) (2011) 0.76
Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab (2014) 0.75
Diabetes Is Associated with Increased Autoreactivity of Mannan-Binding Lectin. J Diabetes Res (2017) 0.75
Identification of mannose-binding lectin as a mechanism in progressive immunoglobulin A nephropathy. Int J Clin Exp Pathol (2015) 0.75
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Nephropathy in diabetes. Diabetes Care (2004) 4.08
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int (2003) 3.95
Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol (2012) 3.86
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care (2003) 3.12
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int (2002) 2.92
Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol (2001) 2.90
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int (2011) 2.52
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol (2006) 2.51
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant (2002) 2.41
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens (2007) 2.27
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens (2013) 2.15
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med (2004) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med (2009) 2.10
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care (2003) 2.08
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care (2010) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Progression of nephropathy in type 2 diabetic patients. Kidney Int (2004) 2.05
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int (2005) 2.00
Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab (2003) 1.93
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Diabetic nephropathy. Diabetes Care (2003) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol (2006) 1.78
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes (2009) 1.76
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol (2009) 1.75
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem (2004) 1.70
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int (2012) 1.65
Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun (2005) 1.64
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care (2002) 1.61
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61
Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61
Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60
Tight glycemic control protects the myocardium and reduces inflammation in neonatal heart surgery. Ann Thorac Surg (2010) 1.59
Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes (2008) 1.59
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care (2002) 1.57
Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J Leukoc Biol (2011) 1.55
Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J Immunol Methods (2003) 1.54
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int (2005) 1.52
Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med (2003) 1.52
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care (2003) 1.51
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant (2004) 1.49
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care (2005) 1.44